deltatrials
Completed PHASE2 NCT00142181

Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)

Sponsor: Arizona Oncology Associates

Conditions Lymphoplasmacytic Lymphoma Waldenstrom's Macroglobulinemia
Interventions Campath-1H
Updated 6 times since 2017 Last updated: Dec 19, 2012 Started: Mar 31, 2003 Primary completion: Oct 31, 2005 Completion: Jun 30, 2008

Listed as NCT00142181, this PHASE2 trial focuses on Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia and remains completed. Sponsored by Arizona Oncology Associates, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arizona Oncology Associates
  • Bayer
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
  • Northwestern University
  • University of California, Los Angeles
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States